Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $941,000.

  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) rose 19.18% to $261,000 in Q2 2025 from the same period last year, while for Apr 2025 it was $931,000, marking a year-over-year increase of 14.09%. This contributed to the annual value of $941,000 for FY2025, which is 15.32% up from last year.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) amounted to $941,000 in FY2025, which was up 15.32% from $816,000 recorded in FY2024.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $941,000 during FY2025, with a 5-year trough of $537,000 in FY2021.
  • For the 3-year period, KalVista Pharmaceuticals' Depreciation & Amortization (CF) averaged around $825,000, with its median value being $816,000 (2024).
  • Data for KalVista Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY rose of 27.30% (in 2023) over the last 5 years.
  • Over the past 5 years, KalVista Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $537,000 in 2021, then increased by 5.03% to $564,000 in 2022, then grew by 27.30% to $718,000 in 2023, then increased by 13.65% to $816,000 in 2024, then increased by 15.32% to $941,000 in 2025.